GI Innovation
Financials
Valuation Metrics
GI Innovation's Market Cap is ₩5781B. At end of 2025 it was ₩1.1T. Ranked #442 of 2,419 in KR market (top 18%), #159 of 1,638 on KOSDAQ (top 10%), #47 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 578.06B KRW | KR#442/2,419 Sec#47/231 |
| Revenue | 5.50B KRW | KR#2,334/2,419 Sec#192/231 |
| Net Income | -39.14B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 105.53B KRW | KR#1,736/2,419 Sec#137/231 |
| Net Assets | 96.64B KRW | KR#1,443/2,419 Sec#113/231 |
| Employees | 84 | KR#1,779/2,419 Sec#145/231 |
| Value | ||
| P/B | 5.98x | KR#2,263/2,419 Sec#195/231 |
| P/S | 105.10x | KR#2,389/2,419 Sec#208/231 |
| FCF Yield | -6.86% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -40.50% | KR#2,244/2,419 Sec#189/231 |
| ROA | -37.09% | KR#2,342/2,419 Sec#209/231 |
| Op. Margin | -812.10% | KR#2,375/2,419 Sec#212/231 |
| Revenue Growth | 1526.80% | KR#3/2,419 Sec#2/231 |
| Financial Health | ||
| Debt Ratio | 9.20% | KR#119/2,419 Sec#26/231 |
| Total Debt | 1.32B KRW | KR#1,938/2,419 Sec#186/231 |
| FCF | -39.68B KRW | KR#2,035/2,419 Sec#200/231 |
| Cash | 29.02B KRW | KR#1,029/2,419 Sec#71/231 |
| Current Ratio | 6.18x | KR#205/2,419 Sec#40/231 |
| Performance | ||
| 1Y Return | -53.09% | KR#2,163/2,419 Sec#204/231 |
| 1M Return | 2.17% | KR#531/2,419 Sec#38/231 |
| From 52W High | -57.23% | KR#1,788/2,419 Sec#142/231 |
| 1Y MDD | -67.37% | KR#1,854/2,419 Sec#155/231 |
| Trading | ||
| Volume | 178,754 shares | KR#504/2,419 Sec#40/231 |
| Trading Value | 1.61B KRW | KR#576/2,419 Sec#60/231 |
| Foreign Own. | 8.85% | KR#516/2,419 Sec#44/231 |
| Per Share | ||
| EPS | -607 KRW | KR—/2,419 Sec—/231 |
| BPS | 1,498 KRW | KR#2,201/2,419 Sec#191/231 |
Company Info
GI Innovation, established in 2017, is a specialized fusion protein-based new drug research and development company that listed on KOSDAQ under special provisions in 2023. It boasts a diverse pipeline of immune therapeutics, including immuno-oncology drugs and allergy treatments, facilitated by its GI-SMART platform technology for one-stop early discovery. The company has completed technology transfers to Simcere and Yuhan Corporation and entered into a joint clinical trial agreement with MSD, contributing to the creation of a global innovative new drug pipeline. GI Innovation is headquartered in Songpa-gu, Seoul.